Previous long-term research has documented that progressive T2D with β-cell deterioration determines the onset and rate of progression, with secondary treatment failure and the need for insulin [5,6] until the A Diabetes Outcome Progression Trial (ADOPT) study showed that the main classes of antidiabetics used in monotherapy resulted in a progressive glycemic increase over time, which may reflect a reduction in insulin secretion [7]. The gene discussed is INS; the disease is type 2 diabetes mellitus.